"If the extra cost to health-care systems turns out to be something like $1000 per patient, then Pennsaid starts to look very, very good."
Good point Jim, and if the cost of Pennsaid could be reduced, then our topical may look even better in a cost/benefit analysis done by the formularies and HMO's. Then Cal Gary's 1% market share may be boosted out to 2,3,or4%. Any further out, and we will probably start getting some competition. Russet's probably in the basement now, mixing up a Pennsaid knockoff.
Napoleon once said he'd rather have lucky generals than smart ones. How lucky can this new management crew get. On the day that Vioxx gets pulled, Pennsaid has a new trial published in the Journal of Rheumatology. Wow, very impressive!
Thinking tonight about all the people who gave me the blank stare when I suggested Pennsaid, telling me that the doc has them on Vioxx and it works real good.
And yes Mr. Kayne, a little humble pie is sitting beside my keyboard as I type this. |
